Bullish Lilly Adds New Alzheimer's Candidate To Clinical Portfolio
Undaunted by its recent disappointment with solanezumab, Eli Lilly is adding another clinical-stage Alzheimer's disease candidate to its portfolio through an agreement with AstraZeneca.
You may also be interested in...
The Swiss biotech, AC Immune, has identified further antibodies aimed at targets in neurodegenerative diseases that could complement its work in beta-amyloid and tau-based approaches to conditions like Alzheimer's disease.
Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.